These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36934549)

  • 1. NIRDye 812: A molecular platform tailored for multimodal bioimaging applications of targeted fluorescence- and photoacoustic-guided surgery.
    Hettie KS; Chin FT
    J Photochem Photobiol B; 2023 May; 242():112683. PubMed ID: 36934549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Off-Peak Near-Infrared-II (NIR-II) Bioimaging of an Immunoconjugate Having Peak Fluorescence Emission in the NIR-I Spectral Region for Improving Tumor Margin Delineation.
    Hettie KS; Teraphongphom NT; Ertsey R; Chin FT
    ACS Appl Bio Mater; 2020 Dec; 3(12):8658-8666. PubMed ID: 35019636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence-guided resection of experimental malignant glioma using cetuximab-IRDye 800CW.
    Warram JM; de Boer E; Korb M; Hartman Y; Kovar J; Markert JM; Gillespie GY; Rosenthal EL
    Br J Neurosurg; 2015; 29(6):850-8. PubMed ID: 26073144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of near-infrared (NIR) fluorescently labeled cetuximab as a potential tool for fluorescence-guided surgery.
    Saccomano M; Dullin C; Alves F; Napp J
    Int J Cancer; 2016 Nov; 139(10):2277-89. PubMed ID: 27428782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical evaluation of EpCAM-binding designed ankyrin repeat proteins (DARPins) as targeting moieties for bimodal near-infrared fluorescence and photoacoustic imaging of cancer.
    Houvast RD; Badr N; March T; de Muynck LDAN; Sier VQ; Schomann T; Bhairosingh S; Baart VM; Peeters JAHM; van Westen GJP; Plückthun A; Burggraaf J; Kuppen PJK; Vahrmeijer AL; Sier CFM
    Eur J Nucl Med Mol Imaging; 2024 Jul; 51(8):2179-2192. PubMed ID: 37642704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor-Specific Imaging with Angiostamp800 or Bevacizumab-IRDye 800CW Improves Fluorescence-Guided Surgery over Indocyanine Green in Peritoneal Carcinomatosis.
    Josserand V; Bernard C; Michy T; Guidetti M; Vollaire J; Coll JL; Hurbin A
    Biomedicines; 2022 May; 10(5):. PubMed ID: 35625796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Near-infrared fluorescence laparoscopy of the cystic duct and cystic artery: first experience with two new preclinical dyes in a pig model.
    van den Bos J; Al-Taher M; Hsien SG; Bouvy ND; Stassen LPS
    Surg Endosc; 2017 Oct; 31(10):4309-4314. PubMed ID: 28271266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrin αvβ3-targeted IRDye 800CW near-infrared imaging of glioblastoma.
    Huang R; Vider J; Kovar JL; Olive DM; Mellinghoff IK; Mayer-Kuckuk P; Kircher MF; Blasberg RG
    Clin Cancer Res; 2012 Oct; 18(20):5731-40. PubMed ID: 22914772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanocolloidal albumin-IRDye 800CW: a near-infrared fluorescent tracer with optimal retention in the sentinel lymph node.
    Heuveling DA; Visser GW; de Groot M; de Boer JF; Baclayon M; Roos WH; Wuite GJ; Leemans CR; de Bree R; van Dongen GA
    Eur J Nucl Med Mol Imaging; 2012 Jul; 39(7):1161-8. PubMed ID: 22349719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Near-infrared fluorescence laparoscopy of the ureter with three preclinical dyes in a pig model.
    van den Bos J; Al-Taher M; Bouvy ND; Stassen LPS
    Surg Endosc; 2019 Mar; 33(3):986-991. PubMed ID: 30478696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a Suitable Untargeted Agent for the Clinical Translation of ABY-029 Paired-Agent Imaging in Fluorescence-Guided Surgery.
    Wang C; Xu X; Hodge S; Chen EY; Hoopes PJ; Tichauer KM; Samkoe KS
    Mol Imaging Biol; 2023 Feb; 25(1):97-109. PubMed ID: 34642897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraoperative Molecular Fluorescence Imaging of Pancreatic Cancer by Targeting Vascular Endothelial Growth Factor: A Multicenter Feasibility Dose-Escalation Study.
    Mulder BGS; Koller M; Duiker EW; Sarasqueta AF; Burggraaf J; Meijer VE; Vahrmeijer AL; Hoogwater FJH; Bonsing BA; van Dam GM; Mieog JSD; Pranger BK
    J Nucl Med; 2023 Jan; 64(1):82-89. PubMed ID: 35680414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Near-Infrared Imaging Agents Targeting the PTPmu Tumor Biomarker.
    Johansen ML; Vincent J; Rose M; Sloan AE; Brady-Kalnay SM
    Mol Imaging Biol; 2023 Aug; 25(4):744-757. PubMed ID: 36695968
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.